On August 5, 2019, the SEC filed an emergency action against Arbutus Biopharma Corp. ("AB-506") and its CEO, Bill Collier, for acting as unregistered brokers in the company's hepatitis B clinical trial.  The SEC's complaint alleges that AB-506 and AB-729 violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  According to the complaint, AB-506 and AB-729 are potent oral capsid inhibitors with the potential to significantly reduce the number of hepatitis B patients who are infected with the virus.  The complaint further alleges that AB-506 and AB-729 are a potent captive inhibitors and warrants further development.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, charges Collier with violating the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder and Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act.  Without admitting or denying the allegations in the SEC's complaint, the company has consented to the entry of a final judgment that permanently enjoins it from violating Section 10(b) of the Exchange Act, and orders it to pay disgorgement of ill-gotten gains plus interest, penalties, and injunctive relief.  The settlement is subject to court approval.  The SEC's investigation was conducted by Keay Nakae, Chardan Jeffrey Tan, and Jeffrey Tan of B. Riley FBR.  The SEC's litigation will be led by William Collier and supervised by Keay Nakae.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.